Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Manipulation of Gut Microbiota Influences Immune Responses, Axon Preservation, and Motor Disability in a Model of Progressive Multiple Sclerosis.

Mestre L, Carrillo-Salinas FJ, Mecha M, Feliú A, Espejo C, Álvarez-Cermeño JC, Villar LM, Guaza C.

Front Immunol. 2019 Jun 14;10:1374. doi: 10.3389/fimmu.2019.01374. eCollection 2019.

2.

Heart Inflammation: Immune Cell Roles and Roads to the Heart.

Carrillo-Salinas FJ, Ngwenyama N, Anastasiou M, Kaur K, Alcaide P.

Am J Pathol. 2019 Aug;189(8):1482-1494. doi: 10.1016/j.ajpath.2019.04.009. Epub 2019 May 18. Review.

PMID:
31108102
3.

T-cell recruitment to the heart: friendly guests or unwelcome visitors?

Blanton RM, Carrillo-Salinas FJ, Alcaide P.

Am J Physiol Heart Circ Physiol. 2019 Jul 1;317(1):H124-H140. doi: 10.1152/ajpheart.00028.2019. Epub 2019 May 10.

PMID:
31074651
4.

Sialomucin CD43 regulates T helper type 17 cell intercellular adhesion molecule 1 dependent adhesion, apical migration and transendothelial migration.

Velázquez FE, Anastasiou M, Carrillo-Salinas FJ, Ngwenyama N, Salvador AM, Nevers T, Alcaide P.

Immunology. 2019 May;157(1):52-69. doi: 10.1111/imm.13047. Epub 2019 Feb 17.

PMID:
30690734
5.

Therapeutic potential of extracellular vesicles derived from human mesenchymal stem cells in a model of progressive multiple sclerosis.

Laso-García F, Ramos-Cejudo J, Carrillo-Salinas FJ, Otero-Ortega L, Feliú A, Gómez-de Frutos M, Mecha M, Díez-Tejedor E, Guaza C, Gutiérrez-Fernández M.

PLoS One. 2018 Sep 19;13(9):e0202590. doi: 10.1371/journal.pone.0202590. eCollection 2018.

6.

Gut microbiota, cannabinoid system and neuroimmune interactions: New perspectives in multiple sclerosis.

Mestre L, Carrillo-Salinas FJ, Mecha M, Feliú A, Guaza C.

Biochem Pharmacol. 2018 Nov;157:51-66. doi: 10.1016/j.bcp.2018.08.037. Epub 2018 Aug 30. Review.

PMID:
30171835
7.

Th1 effector T cells selectively orchestrate cardiac fibrosis in nonischemic heart failure.

Nevers T, Salvador AM, Velazquez F, Ngwenyama N, Carrillo-Salinas FJ, Aronovitz M, Blanton RM, Alcaide P.

J Exp Med. 2017 Nov 6;214(11):3311-3329. doi: 10.1084/jem.20161791. Epub 2017 Oct 2.

8.

2-Arachidonoylglycerol Reduces Proteoglycans and Enhances Remyelination in a Progressive Model of Demyelination.

Feliú A, Bonilla Del Río I, Carrillo-Salinas FJ, Hernández-Torres G, Mestre L, Puente N, Ortega-Gutiérrez S, López-Rodríguez ML, Grandes P, Mecha M, Guaza C.

J Neurosci. 2017 Aug 30;37(35):8385-8398. doi: 10.1523/JNEUROSCI.2900-16.2017. Epub 2017 Jul 27.

9.

Gut dysbiosis and neuroimmune responses to brain infection with Theiler's murine encephalomyelitis virus.

Carrillo-Salinas FJ, Mestre L, Mecha M, Feliú A, Del Campo R, Villarrubia N, Espejo C, Montalbán X, Álvarez-Cermeño JC, Villar LM, Guaza C.

Sci Rep. 2017 Mar 14;7:44377. doi: 10.1038/srep44377.

10.

Correction: Novel Insights into the Multiple Sclerosis Risk Gene ANKRD55.

Lopez de Lapuente A, Feliú A, Ugidos N, Mecha M, Mena J, Astobiza I, Riera J, Carrillo-Salinas FJ, Comabella M, Montalban X, Alloza I, Guaza C, Vandenbroeck K.

J Immunol. 2016 Nov 15;197(10):4177. No abstract available.

11.

Microglia activation states and cannabinoid system: Therapeutic implications.

Mecha M, Carrillo-Salinas FJ, Feliú A, Mestre L, Guaza C.

Pharmacol Ther. 2016 Oct;166:40-55. doi: 10.1016/j.pharmthera.2016.06.011. Epub 2016 Jun 29. Review.

PMID:
27373505
12.

Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.

Morales P, Gómez-Cañas M, Navarro G, Hurst DP, Carrillo-Salinas FJ, Lagartera L, Pazos R, Goya P, Reggio PH, Guaza C, Franco R, Fernández-Ruiz J, Jagerovic N.

J Med Chem. 2016 Jul 28;59(14):6753-6771. doi: 10.1021/acs.jmedchem.6b00397. Epub 2016 Jul 6.

13.

Novel Insights into the Multiple Sclerosis Risk Gene ANKRD55.

Lopez de Lapuente A, Feliú A, Ugidos N, Mecha M, Mena J, Astobiza I, Riera J, Carrillo-Salinas FJ, Comabella M, Montalban X, Alloza I, Guaza C, Vandenbroeck K.

J Immunol. 2016 Jun 1;196(11):4553-65. doi: 10.4049/jimmunol.1501205. Epub 2016 May 4. Erratum in: J Immunol. 2016 Nov 15;197(10 ):4177.

14.

The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors.

Moreno-Martet M, Feliú A, Espejo-Porras F, Mecha M, Carrillo-Salinas FJ, Fernández-Ruiz J, Guaza C, de Lago E.

Mult Scler Relat Disord. 2015 Nov;4(6):505-11. doi: 10.1016/j.msard.2015.08.001. Epub 2015 Aug 5.

PMID:
26590655
15.

Endocannabinoids drive the acquisition of an alternative phenotype in microglia.

Mecha M, Feliú A, Carrillo-Salinas FJ, Rueda-Zubiaurre A, Ortega-Gutiérrez S, de Sola RG, Guaza C.

Brain Behav Immun. 2015 Oct;49:233-45. doi: 10.1016/j.bbi.2015.06.002. Epub 2015 Jun 15.

PMID:
26086345
16.

PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis.

Mestre L, Redondo M, Carrillo-Salinas FJ, Morales-García JA, Alonso-Gil S, Pérez-Castillo A, Gil C, Martínez A, Guaza C.

Br J Pharmacol. 2015 Sep;172(17):4277-90. doi: 10.1111/bph.13192. Epub 2015 Jul 14.

17.

A Sativex(®) -like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis.

Feliú A, Moreno-Martet M, Mecha M, Carrillo-Salinas FJ, de Lago E, Fernández-Ruiz J, Guaza C.

Br J Pharmacol. 2015 Jul;172(14):3579-95. doi: 10.1111/bph.13159. Epub 2015 May 20.

18.

A cannabigerol derivative suppresses immune responses and protects mice from experimental autoimmune encephalomyelitis.

Carrillo-Salinas FJ, Navarrete C, Mecha M, Feliú A, Collado JA, Cantarero I, Bellido ML, Muñoz E, Guaza C.

PLoS One. 2014 Apr 11;9(4):e94733. doi: 10.1371/journal.pone.0094733. eCollection 2014.

19.

Brain innate immunity in the regulation of neuroinflammation: therapeutic strategies by modulating CD200-CD200R interaction involve the cannabinoid system.

Hernangómez M, Carrillo-Salinas FJ, Mecha M, Correa F, Mestre L, Loría F, Feliú A, Docagne F, Guaza C.

Curr Pharm Des. 2014;20(29):4707-22. Review.

20.

Mobilization of progenitors in the subventricular zone to undergo oligodendrogenesis in the Theiler's virus model of multiple sclerosis: implications for remyelination at lesions sites.

Mecha M, Feliú A, Carrillo-Salinas FJ, Mestre L, Guaza C.

Exp Neurol. 2013 Dec;250:348-52. doi: 10.1016/j.expneurol.2013.10.011. Epub 2013 Oct 19.

21.

Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors.

Mecha M, Feliú A, Iñigo PM, Mestre L, Carrillo-Salinas FJ, Guaza C.

Neurobiol Dis. 2013 Nov;59:141-50. doi: 10.1016/j.nbd.2013.06.016. Epub 2013 Jul 11.

22.

Viral models of multiple sclerosis: neurodegeneration and demyelination in mice infected with Theiler's virus.

Mecha M, Carrillo-Salinas FJ, Mestre L, Feliú A, Guaza C.

Prog Neurobiol. 2013 Feb-Mar;101-102:46-64. doi: 10.1016/j.pneurobio.2012.11.003. Epub 2012 Nov 29.

PMID:
23201558
23.

Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress.

Mecha M, Torrao AS, Mestre L, Carrillo-Salinas FJ, Mechoulam R, Guaza C.

Cell Death Dis. 2012 Jun 28;3:e331. doi: 10.1038/cddis.2012.71.

Supplemental Content

Loading ...
Support Center